Cargando…
The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies.
The Organisation for Economic Co-operation and Development has completed phase 2 of an international validation program for the rodent uterotrophic bioassay. This portion of phase 2 assessed the reproducibility of the assay with a battery of positive and negative test substances. Positive agonists o...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241660/ https://www.ncbi.nlm.nih.gov/pubmed/12948897 |
_version_ | 1782125468272558080 |
---|---|
author | Kanno, Jun Onyon, Lesley Peddada, Shyamal Ashby, John Jacob, Elard Owens, William |
author_facet | Kanno, Jun Onyon, Lesley Peddada, Shyamal Ashby, John Jacob, Elard Owens, William |
author_sort | Kanno, Jun |
collection | PubMed |
description | The Organisation for Economic Co-operation and Development has completed phase 2 of an international validation program for the rodent uterotrophic bioassay. This portion of phase 2 assessed the reproducibility of the assay with a battery of positive and negative test substances. Positive agonists of the estrogen receptor included the potent reference estrogen 17-ethinyl estradiol (EE), and the weak estrogen agonists bisphenol A, genistein, methoxychlor, nonylphenol, and o,p -DDT. The negative test substance or nonagonist was n-dibutylphthalate. The test substances were coded, and prescribed doses of each test substance were administered in 16 laboratories. Two versions of the uterotrophic assay, the intact immature and the adult ovariectomized female rat, were tested and compared using four standardized protocols covering both sc and po administration. Assay reproducibility was compared using a) EE doses identical to those used in phase 1 and in parallel dose-response studies, b) single doses of the weak agonists identical to one of five doses from the dose-response studies, and c) a single dose of the negative test substance. The results were reproducible and in agreement both within individual laboratories and across the participating laboratories for the same test substance and protocol. The few exceptions are examined in detail. The reproducibility was achieved despite a variety of different experimental conditions (e.g., variations in animal strain, diet, housing protocol, bedding, vehicle, animal age). In conclusion, both versions of the uterotrophic bioassay and all protocols appear robust, reproducible, and transferable across laboratories and able to detect weak estrogen agonists. These results will be submitted along with other data for independent peer review to provide support for the validation of the uterotrophic bioassay. |
format | Text |
id | pubmed-1241660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
record_format | MEDLINE/PubMed |
spelling | pubmed-12416602005-11-08 The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies. Kanno, Jun Onyon, Lesley Peddada, Shyamal Ashby, John Jacob, Elard Owens, William Environ Health Perspect Research Article The Organisation for Economic Co-operation and Development has completed phase 2 of an international validation program for the rodent uterotrophic bioassay. This portion of phase 2 assessed the reproducibility of the assay with a battery of positive and negative test substances. Positive agonists of the estrogen receptor included the potent reference estrogen 17-ethinyl estradiol (EE), and the weak estrogen agonists bisphenol A, genistein, methoxychlor, nonylphenol, and o,p -DDT. The negative test substance or nonagonist was n-dibutylphthalate. The test substances were coded, and prescribed doses of each test substance were administered in 16 laboratories. Two versions of the uterotrophic assay, the intact immature and the adult ovariectomized female rat, were tested and compared using four standardized protocols covering both sc and po administration. Assay reproducibility was compared using a) EE doses identical to those used in phase 1 and in parallel dose-response studies, b) single doses of the weak agonists identical to one of five doses from the dose-response studies, and c) a single dose of the negative test substance. The results were reproducible and in agreement both within individual laboratories and across the participating laboratories for the same test substance and protocol. The few exceptions are examined in detail. The reproducibility was achieved despite a variety of different experimental conditions (e.g., variations in animal strain, diet, housing protocol, bedding, vehicle, animal age). In conclusion, both versions of the uterotrophic bioassay and all protocols appear robust, reproducible, and transferable across laboratories and able to detect weak estrogen agonists. These results will be submitted along with other data for independent peer review to provide support for the validation of the uterotrophic bioassay. 2003-09 /pmc/articles/PMC1241660/ /pubmed/12948897 Text en |
spellingShingle | Research Article Kanno, Jun Onyon, Lesley Peddada, Shyamal Ashby, John Jacob, Elard Owens, William The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies. |
title | The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies. |
title_full | The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies. |
title_fullStr | The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies. |
title_full_unstemmed | The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies. |
title_short | The OECD program to validate the rat uterotrophic bioassay. Phase 2: coded single-dose studies. |
title_sort | oecd program to validate the rat uterotrophic bioassay. phase 2: coded single-dose studies. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241660/ https://www.ncbi.nlm.nih.gov/pubmed/12948897 |
work_keys_str_mv | AT kannojun theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT onyonlesley theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT peddadashyamal theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT ashbyjohn theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT jacobelard theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT owenswilliam theoecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT kannojun oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT onyonlesley oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT peddadashyamal oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT ashbyjohn oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT jacobelard oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies AT owenswilliam oecdprogramtovalidatetheratuterotrophicbioassayphase2codedsingledosestudies |